News China clears its first drug for chronic hepatitis D Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.
Market Access European biopharma at a crossroads If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.
News Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer Hengrui has achieved a milestone in oncology as retlirafusp alfa is approved in China, its first world market, for gastric cancer.
News China clears GSK's Nucala for COPD GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.
News US BIOSECURE Act passed by Congress The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern'.
Market Access From roasts to billions: Navigating the biopharma investment... At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.